New site to be located at LifeX™ Labs on city’s South Side
Leonhardt's Launchpads, a medtech and biotech innovation and startup accelerator focused on organ regeneration and recovery technologies, today announced its expansion into Pittsburgh with the formation of Leonhardt's Launchpads Pittsburgh. The company will be located at LifeX Labs™ at 2730 Sidney Street, Suite 300.
"The research personnel and facilities in Pittsburgh are simply incredible,” said Dr. Leslie Miller, Chief Medical Officer of Leonhardt's Launchpads Pittsburgh. “We are excited about working with Pittsburgh researchers to advance organ regeneration and recovery technologies. We are especially excited about being accepted into the esteemed LifeX Labs."
"Our core research team made two visits to the Pittsburgh area the past quarter, and we were highly impressed with the talent, facilities and resources for developing organ regeneration and recovery technologies,” said Phil Patton, Pittsburgh-based EVP of Business Development for Leonhardt's Launchpads Pittsburgh and President of KidneyCell. “We believe having a local presence will enhance our research collaborations with multiple institutions in the Pittsburgh region."
“We are pleased to welcome Leonhardt's Launchpads to LifeX labs,” said Dr. Dietrich Stephan, CEO and Founder of LifeX. “They have an outstanding scientific and clinical team and a proven track record of moving breakthrough innovations to commercial success. This is another example of the talent, capital and technologies that LifeX is attracting to the Pittsburgh region."
The Leonhardt's Launchpads Pittsburgh innovation accelerator will be focused on bioelectric and biologics-based organ regeneration and recovery technologies in these areas:
1. Heart & Cardiovascular.
3. Cosmetic & Personal Care.
4. Major Organ Regeneration.
The company is already exploring research collaborations for the following startups and technologies in the Pittsburgh region:
- KidneyCell - www.kidney-cell.com - kidney regeneration.
- Livercell - https://leonhardtventures.com/livercell/ - liver regeneration.
- BioLeonhardt - www.bioleonhardt.com - heart and skeletal muscle regeneration.
- Cerebracell - www.cerebracell.com - brain regeneration.
- CancerCell - www.cancercellinc.com - bioelectric cancer treatment.
- Vascustim - www.vascustim.com - diabetic ulcer treatment.
- SkinStim - www.skin-stim.com - skin regeneration.
- HairCell - www.haircellstim.com - hair regeneration.
- OrthoStim - www.ortho-stim.com - joint (knees) regeneration.
- OrthodontiCell - www.orthodonticell.com - bioelectric teeth straightening.
- RegenaLung - https://leonhardtventures.com/regenalung/ - lung regeneration, COPD treatment.
- PolypStim - www.polypstim.com - bioelectric polyp, fibroid and cyst treatment.
- PressureStim -https://pressurestim.com- bioelectric blood pressure control.
- InStim - www.instimcell.com - bioelectric inflammation management.
- DentaCell - www.dentacellaccelerator.com - bioelectric and biologics for oral health.
- MyoStim ED www.erectistim.com - bioelectric erectile dysfunction treatment
- Second Heart Assist, Inc. - www.secondheartinc.com - wireless powered circulatory assist support.
The business model for Leonhardt's Launchpads Pittsburgh is to advance organ specific innovations and their corresponding organ focused startups through first-in-human results and then seek a strategic partner to advance the development into full commercialization. It is expected that about five innovations each year for the next six years will be through first-in-human studies.
The ultimate, long-term goal of the Leonhardt's Launchpads Pittsburgh team, working in collaboration with most of the Pittsburgh based major research institutions, is to develop a whole-body regeneration chamber, similar to a womb for adults. The BioLeonhardt Whole Body Regeneration Chamber would be able to regenerate all organs and detect and eradicate cancer in its earliest stages of development. The team is starting at first more modestly one organ at a time.
See the new Leonhardt's Launchpads Pittsburgh web site at www.leonhardtpittsburgh.com for more information.
About Leonhardt Ventures:
Leonhardt Ventures is the commercialization arm for the inventions of Howard J. Leonhardt and the majority owner of Leonhardt's Launchpads by Cal-X Stars Business Accelerator, Inc., Leonhardt's Launchpads Australia, Leonhardt's Launchpads Utah, Inc. and now Leonhardt's Launchpads Pittsburgh. In the 1980's the team patented and pioneered cardiovascular balloon catheters, in the 1990's stent grafts, intravascular lung catheters and percutaneous heart valves and since 1999 the focus has been on organ regeneration with a combination of bioelectrics and biologics. The Leonhardt team developed and patented stent graft today has world leading market share as a product of Medtronic Vascular for repairing aortic aneurysms without surgery. There are currently 30 startups in the Leonhardt's Launchpads 2018 portfolio. 23+ issued and pending patents - https://patents.justia.com/inventor/howard-j-leonhardt
Contact: Howard Leonhardt, 424-291-2133 [email protected]
At LifeX™ we believe the biggest investment opportunity is creating novel types of solutions that result from the convergence of different silos of expertise and address global unmet health needs. LifeX focuses on building companies that are developing therapeutics, diagnostics, medical devices and digital health companies with the potential to return billions of dollars and save millions of lives. LifeX takes an active and engaged approach to venture funding to ensure entrepreneurs get the guidance, resources and support needed to tackle these prevalent, notoriously intractable and horrific diseases.
Contact: Wes Conard
Disclaimer: All product developments mentioned are early stage and unproven yet to be either safe or effective. Any product performance claims implied are not meant to be absolute or deemed proven via statistically significant and powered evaluations. These are early stage optimistic observations only. The company may not have the resources to fully develop these products. Any patents licensed, issued or pending may not be kept active or held. Any strategic partnerships mentioned may not be maintained. Any forward looking statements may be subject to change forward without notice. The communication reflects the optimism of founders and developers only. As an investment these startups must be considered very high risk not suitable for many and restricted to verified accredited and sophisticated experienced investors only at this time. A substantial portion of the engaged team derives sources of income from other sources and may not be fully focused on accomplishing the goals of the organization which may impede or delay progress.